Methocel e15 premium lv mw 40 000

Griseofulvin (GF; Letco Medical, Decatur, AL, USA) was selected as a model BCS class II drug. Pharmaceutical grade amorphous hydrophilic silica (M5P, Cabot Corporation, MA, USA) with a primary particle size of 16 nm was used as the coating material for milled coated GF (MC-GF) particles. Low molecular weight hydroxypropyl methylcellulose (HPMC; Methocel E15 Premium LV, Mw∼ 40,000, The Dow Chemical Company, Midland, MI, USA) and glycerin (Sigma-Aldrich, Saint Louis, MO, USA) were used as the film former and the film plasticizer, respectively. Sodium dodecyl sulfate (SDS) (Sigma-Aldrich, Saint Louis, MO, USA) was used as the surfactant in the dissolution media. All other materials were used as-received.

Fenofibrate (FNB; Jai Radhe Sales, Ahmedabad, India) was selected as a model BCS Class II poorly water-soluble drug. Pharmaceutical grade amorphous hydrophilic silica (M5P, Cabot Corporation, MA, USA) with a primary particle size of 16 nm was used as the coating material for milled coated FNB (MC-FNB) particles to enhance wettability and reduce agglomeration of micronized FNB particles. Low molecular weight hydroxypropyl methylcellulose (HPMC; Methocel E15 Premium LV, Mw∼40,000, The Dow Chemical Company, Midland, MI) and glycerin (Sigma–Aldrich, Saint Louis, MO, USA) were used as the film former and the film plasticizer, respectively. Sodium starch glycolate (SSG; Primojel, Princeton, NJ, USA) and croscarmellose sodium (CCS; Ac-Di-Sol, Newark, DE, USA) were used as a film filler and viscosity enhancer. Sodium dodecyl sulfate (SDS) (Sigma–Aldrich, Saint Louis, MO, USA) was used as the surfactant in the dissolution media. All materials were used as received, except for the MC-FNB, for which the procedure is described in the next section.